Last updated: May 23, 2026
ENSTILAR suppliers: What companies make and supply Enstilar (calcipotriene/betamethasone) for pharmacies and hospitals?
Enstilar is a combination product (calcipotriene 0.005% and betamethasone dipropionate 0.064%) marketed as a foam and manufactured/ supplied in the US under an FDA-approved NDA with supply chains that include the drug substance and finished-dose manufacturers, plus contract manufacturing and packaging partners.
Supplier mapping in practice is typically structured across:
- Finished-dose manufacturer (drug product): the company listed as the NDA holder’s manufacturing site(s) on FDA labeling and GMP-related records.
- Drug substance suppliers: manufacturers of calcipotriene and betamethasone dipropionate (active ingredient) used to build the combination.
- Contract manufacturing/packaging: companies producing foam canisters, valves/actuators, propellant filling, and carton/label packaging for the NDA holder.
- Distribution: wholesalers and direct-to-account distribution depending on the commercial model of the NDA holder.
No actionable, company-specific supplier list can be produced from the information available in this prompt alone.
What companies supply Enstilar (calcipotriene and betamethasone) to the US market?
What “suppliers” usually means for Enstilar
- NDA holder and commercial marketer responsible for finished product release.
- Contract manufacturer(s) for foam filling, canister packing, and labeling.
- Active pharmaceutical ingredient (API) manufacturers for calcipotriene and betamethasone dipropionate.
- Third-party logistics and distribution partners.
Where Enstilar supplier data is normally sourced
- FDA labeling and “manufactured for” statements (package insert and prescribing information).
- FDA drug product listing and product code records.
- DMF and supplier traceability for API (confidential in practice but partially reflected in public records).
- Corporate supplier disclosures in annual reports and supply chain filings.
Who manufactures the finished-dose Enstilar foam canisters and valves?
Foam corticosteroid and vitamin D analog combination products require supplier capabilities that usually split into:
- Propellant formulation and filling
- Valve/actuator procurement
- Canister washing, filling, crimping, and leak testing
- Labeling and cartonization
Publicly actionable supplier identification requires the specific Enstilar label/manufacturer line and the GMP site listing for the finished dosage form.
Which companies supply calcipotriene API and betamethasone dipropionate API for Enstilar?
Enstilar uses:
- Calcipotriene (vitamin D analog)
- Betamethasone dipropionate (topical corticosteroid)
API supply chains commonly involve:
- Steroid intermediate production
- Chemical synthesis and crystallization control for polymorph and particle size
- GMP batch release to the finished-dose manufacturer
Public supplier identification depends on whether the NDA labeling or public regulatory filings disclose the API manufacturing sites or whether reliance is on DMFs with non-publicized manufacturing details.
What is Enstilar’s FDA-listed manufacturer and how do you verify it?
For finished-dose supplier verification, the authoritative path is:
- Review the US prescribing information and the “Manufactured for” or “Distributed by” statements on current packaging.
- Cross-check with FDA labeling content and product listing records that include manufacturing site information.
A supplier list cannot be generated accurately without the specific labeled manufacturer/distributor lines for the current US market presentation.
Which distributors supply Enstilar to pharmacies and hospitals?
Distribution is typically executed through:
- National wholesalers (standard channel for most branded topicals)
- Specialty distributors or direct-to-provider programs for inventory and reimbursement workflows
The exact distributor names vary by account and contract year and cannot be reliably extracted from the prompt alone without the product’s current US commercial distribution statement.
How do generic or biosimilar “supplier” dynamics affect Enstilar supply risk?
Even though Enstilar is a small-molecule topical combination (not a biologic), supplier risk still matters due to:
- Canister valve sourcing constraints
- Propellant procurement and formulation stability
- API production capacity for both actives
- GMP site availability for foam filling
A supplier-specific risk assessment requires the actual named manufacturers and contract sites for Enstilar’s finished dose and APIs.
Key Takeaways
- “Suppliers for ENSTILAR” can include the NDA-marketing party, finished-dose manufacturer, API makers, packaging/foam-filling partners, and distributors.
- A company-specific supplier list for Enstilar requires the current Enstilar labeling/manufacturer lines and/or FDA listing records for the finished dosage form and manufacturing sites.
- The information provided in the prompt is insufficient to produce a complete, accurate, named supplier roster.
FAQs
- How do I identify the contract manufacturer for Enstilar foam?
- Which API manufacturers make calcipotriene and betamethasone dipropionate for Enstilar?
- What do Enstilar “manufactured for” and “distributed by” lines tell you about suppliers?
- How can foam canister valve and actuator suppliers impact Enstilar availability?
- What supply chain bottlenecks are common for topical steroid/vitamin D foam products like Enstilar?
References
- U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
- U.S. Food and Drug Administration. Drug labeling and prescribing information for ENSTILAR (calcipotriene and betamethasone dipropionate) topical foam.
